Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Mylan Stories

2014-02-12 12:30:26

LONDON, Feb. 12, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Brazilian Pharmaceutical Market 2014-2024Report DetailsDrug selling in Brazil - this new analysis shows you trends, opportunities, and revenuesDo you want to assess the future of pharmaceuticals in Brazil? See what lies ahead, then. Visiongain's new report gives you revenue predictions, helping your work. There you discover financial results, trends, opportunities, and sales forecasts.So...

2014-02-11 12:26:51

PITTSBURGH, Feb. 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast, including a slide presentation, on Thursday, Feb. 27, 2014, at 10:00 a.m. ET, to review the company's financial results for the fourth quarter and year ended Dec. 31, 2013. The company also will be providing its financial guidance for 2014. Mylan will release its financial results on Feb. 27 before the market opens. The dial-in number to access the...

2014-02-03 00:21:09

Availability of 150 mg formulation increases dosing convenience and flexibility MUMBAI and PITTSBURGH, Feb. 3, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India. The product, which will be marketed by Mylan under the brand name Hertraz(TM), is a biosimilar to Roche's...

2014-01-31 00:21:48

PITTSBURGH and MUMBAI, India, Jan. 31, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its India-based subsidiary Mylan Pharmaceuticals Private Limited has been named Gilead Sciences, Inc.'s (Nasdaq: GILD) exclusive branded medicines business partner for India. Under the agreement, Mylan will market and distribute in India Gilead's: -- HIV therapies Viread(® )(tenofovir disoproxil fumarate), Truvada(®) (emtricitabine/tenofovir disoproxil fumarate) and the...

2014-01-29 16:28:52

MALVERN, Pa., Jan. 29, 2014 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today confirmed that the United States District Court for the District of Delaware ruled that United States Patent No. 5,464,864, Endo's patent covering frovatriptan, the active ingredient in FROVA(® )(frovatriptan succinate) tablets, is valid and infringed. The Court's decision prevents Mylan from marketing its generic version of FROVA(®) in the U.S. before Endo's patent expires November 8, 2015,...

2014-01-23 16:24:38

PITTSBURGH, Jan. 23, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg. This product is the generic version of Novo Nordisk's Prandin(®), which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.(1) The company received final approval from the U.S. Food and Drug Administration (FDA) for its...

2014-01-20 12:24:57

LONDON, Jan. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Analyzing the Global Market for Active Pharmaceutical Ingredients The global market for active pharmaceutical ingredients has been growing steadily in recent years. However, the recent economic recession slowed down the growth of the industry as investments made by the major players went down significantly. Furthermore with a large number of blockbuster drugs going off patent by the...

2014-01-09 08:27:16

PITTSBURGH, Jan. 9, 2014 /PRNewswire/ -- Mylan, Inc. (Nasdaq: MYL) today announced that Zyomyx's MyT4(TM) point-of-care CD4 diagnostic test has received the CE Certificate of Conformity in the European Union, an important step toward launching this innovative test and expanding access to affordable, accessible and reliable diagnostics for people living with HIV globally. As a result, the MyT4(TM) CD4 test can now bear the CE Mark, which demonstrates that the MyT4(TM) CD4 test complies...

2014-01-09 08:26:46

- Company awarded 180 days marketing exclusivity on the 360 mg strength - PITTSBURGH, Jan. 9, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Mycophenolic Acid Delayed-release Tablets, 180 mg and 360 mg. This product is the generic version of Novartis' Myfortic(®) Delayed-release Tablets. Mylan was the first company to have filed a substantially complete Abbreviated New Drug Application (ANDA)...

2014-01-08 16:25:55

PITTSBURGH, Jan. 8, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the appointment of Adele Gulfo as executive vice president, Global Collaboration and Strategic Operations. Gulfo will serve as a member of Mylan's executive leadership team. Prior to joining Mylan, Gulfo served as regional president of Latin America in Pfizer's Emerging Markets Business Unit. In this capacity, she led a team of over 4,000 colleagues operating across more than 23 countries. In 2012,...